VIMIAN Stock Overview
Vimian Group AB (publ) engages in the animal health business worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Vimian Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr30.40 |
| 52 Week High | kr37.96 |
| 52 Week Low | kr20.08 |
| Beta | 1.52 |
| 1 Month Change | 2.91% |
| 3 Month Change | 9.51% |
| 1 Year Change | -14.99% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.42% |
Recent News & Updates
Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 18
Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate
Apr 09Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital
Feb 13Recent updates
Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 18Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate
Apr 09Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital
Feb 13Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues
Jan 08Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching
Dec 03There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital
Nov 01Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 92% Above Its Share Price
Aug 27When Should You Buy Vimian Group AB (publ) (STO:VIMIAN)?
Jul 19Are Investors Undervaluing Vimian Group AB (publ) (STO:VIMIAN) By 27%?
May 19Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
Apr 04Calculating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)
Jan 06Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
Dec 09Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 38% Discount?
Aug 25We Like These Underlying Return On Capital Trends At Vimian Group (STO:VIMIAN)
Jun 18Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 34% Discount?
May 19Does This Valuation Of Vimian Group AB (publ) (STO:VIMIAN) Imply Investors Are Overpaying?
Feb 07Risks Still Elevated At These Prices As Vimian Group AB (publ) (STO:VIMIAN) Shares Dive 28%
Nov 30Shareholder Returns
| VIMIAN | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -5.6% | -3.4% | -1.6% |
| 1Y | -15.0% | -13.6% | 7.8% |
Return vs Industry: VIMIAN underperformed the Swedish Medical Equipment industry which returned -13.6% over the past year.
Return vs Market: VIMIAN underperformed the Swedish Market which returned 7.8% over the past year.
Price Volatility
| VIMIAN volatility | |
|---|---|
| VIMIAN Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: VIMIAN has not had significant price volatility in the past 3 months.
Volatility Over Time: VIMIAN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1,100 | Patrik Eriksson | vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
| VIMIAN fundamental statistics | |
|---|---|
| Market cap | kr15.88b |
| Earnings (TTM) | kr114.59m |
| Revenue (TTM) | kr3.86b |
138.6x
P/E Ratio4.1x
P/S RatioIs VIMIAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIMIAN income statement (TTM) | |
|---|---|
| Revenue | €331.73m |
| Cost of Revenue | €102.30m |
| Gross Profit | €229.43m |
| Other Expenses | €219.59m |
| Earnings | €9.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 0.019 |
| Gross Margin | 69.16% |
| Net Profit Margin | 2.97% |
| Debt/Equity Ratio | 57.4% |
How did VIMIAN perform over the long term?
See historical performance and comparison